Quotient (NASDAQ:QTNT) released its quarterly earnings data on Monday. The company reported ($0.47) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.08, reports. Quotient had a negative net margin of 404.29% and a negative return on equity of 13,050.41%.
Shares of Quotient (NASDAQ:QTNT) traded up $0.11 during trading on Monday, hitting $2.99. 1,019,248 shares of the stock were exchanged, compared to its average volume of 477,248. The company has a market capitalization of $131.21, a PE ratio of -1.04 and a beta of 0.74. Quotient has a 52 week low of $2.78 and a 52 week high of $7.74. The company has a debt-to-equity ratio of -5.17, a quick ratio of 0.86 and a current ratio of 1.36.
A number of research firms have commented on QTNT. Zacks Investment Research raised shares of Quotient from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Jefferies Group reduced their target price on shares of Quotient from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Wednesday, November 1st. Finally, BTIG Research reissued a “buy” rating and issued a $12.00 target price on shares of Quotient in a research report on Wednesday, November 1st.
Several institutional investors have recently made changes to their positions in QTNT. The Manufacturers Life Insurance Company bought a new stake in shares of Quotient in the second quarter valued at about $177,000. California State Teachers Retirement System bought a new stake in shares of Quotient in the second quarter valued at about $349,000. Vanguard Group Inc. bought a new stake in shares of Quotient in the second quarter valued at about $523,000. Finally, State Street Corp bought a new stake in shares of Quotient in the second quarter valued at about $1,728,000. 47.39% of the stock is owned by institutional investors.
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.